Background While adalimumab is a mainstay of treatment for moderate to severe chronic
plaque psoriasis, the data regarding optimal treatment intervals for therapeutic maintenance …

Background As psoriatic disease (PD) is a condition characterized by the combination of
inflammatory skin (psoriasis) and osteo‐articular manifestations (psoriatic arthritis), its …

Objective Adalimumab has proven effective in psoriasis; however, secondary failure may
result from the drug9s immunogenicity. Prevalence data on the immunogenicity of …

TNF-α inhibitors, including adalimumab, are increasingly used in the management of
inflammatory cutaneous, gastrointestinal, and rheumatologic diseases. An untoward class …

Background Few studies have compared the efficacy of switching to adalimumab in the real‐
life setting in plaque psoriasis patients. Objective To evaluate the effect of adalimumab in …

Background Drug survival is an indicator for treatment success; insight in predictors
associated with drug survival is important. Objectives (I) To analyse the long‐term drug …

Background: Adalimumab is a fully human IgG1 monoclonal antibody that binds to tumor
necrosis factor (TNF), a key proinflammatory cytokine involved in the pathogenesis of …

Biologics that antagonize the biological activity of tumour necrosis factor (TNF)‐α, namely
infliximab, etanercept and adalimumab, are increasingly used for treatment of immune …

Background Tumor necrosis factor (TNF) antagonists have improved outcomes for patients
with psoriasis, but some patients are unresponsive to treatment (primary failure) or lose an …

Conclusion The exclusion of acute and/or chronic hepatitis before using TNF-alpha
antagonists is recommended but in daily routine often ignored. The presented case …